Mieloma múltiple en Chile: Características clínicas y sobrevida

Background: Mortality rate records are the only data available in Chile about the prognosis of patients with multiple myeloma (MM). Aim To characterize clinical features, survival rate and factors related to mortality in cases with MM treated in six large medical centers in Chile. Material and Metho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Conté L,Guillermo, Figueroa M,Gastón, Lois V,Vivianne, Cabrera C,María Elena, León R,Alvaro, García L,Hernán, Rojas R,Hernán
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Multiple myeloma Myeloma proteins Neoplasm staging Survival rate
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000900003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007000900003
record_format	dspace
spelling	oai:scielo:S0034-988720070009000032008-05-30Mieloma múltiple en Chile: Características clínicas y sobrevidaConté L,GuillermoFigueroa M,GastónLois V,VivianneCabrera C,María ElenaLeón R,AlvaroGarcía L,HernánRojas R,Hernán Multiple myeloma Myeloma proteins Neoplasm staging Survival rate Background: Mortality rate records are the only data available in Chile about the prognosis of patients with multiple myeloma (MM). Aim To characterize clinical features, survival rate and factors related to mortality in cases with MM treated in six large medical centers in Chile. Material and Method: Retrospective analysis of demographic data, clinical features and survival rate records of patients with MM, collected between 1998 and 2002. Survival curves were generated and a multivariate analysis of factors associated to early mortality was carried out. Results: Data from 245patients aged 38 to 95years (129 women) was collected. Fifty two percent had an IgG myeloma, 25% had and IgA and 6.1% had light chains myeloma. According to Durie and Salmon staging system, 8,2% were in Stage 112.6% in Stage II, 60.5% in Stage III and in 18.8% the information about staging was not available. Fifty percent had an hemoglobin level below 10 g/dL, 30% had a serum creatinine over 2 mg/dL and 28% had a serum calcium level over 10.5 mg/dL. Median survival was 33 months. Twenty percent of patients died within the first six months after diagnosis (early mortality). Predictive factors for early mortality were male sex, thrombocytopenia, anemia, renal failure, hypercalcemia, a beta2-microglobulin >5.5 mg/L and a serum albumin level <3.5 g/dL. There was a correlation between the number of bad prognosis factors present and the probability of early mortality. Conclusions: This group of Chilean patients with MM presented a short survival time, and 20% died within the first six months after diagnosis. More than a half of cases were diagnosed at an advanced stage (Durie and Salmon Stage III). Several factors were associated to early mortality, two of which (beta 2-microglobulin and serum albumin), are included in the new International Staging System for MMinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.9 20072007-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000900003es10.4067/S0034-98872007000900003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Multiple myeloma Myeloma proteins Neoplasm staging Survival rate
spellingShingle	Multiple myeloma Myeloma proteins Neoplasm staging Survival rate Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán Mieloma múltiple en Chile: Características clínicas y sobrevida
description	Background: Mortality rate records are the only data available in Chile about the prognosis of patients with multiple myeloma (MM). Aim To characterize clinical features, survival rate and factors related to mortality in cases with MM treated in six large medical centers in Chile. Material and Method: Retrospective analysis of demographic data, clinical features and survival rate records of patients with MM, collected between 1998 and 2002. Survival curves were generated and a multivariate analysis of factors associated to early mortality was carried out. Results: Data from 245patients aged 38 to 95years (129 women) was collected. Fifty two percent had an IgG myeloma, 25% had and IgA and 6.1% had light chains myeloma. According to Durie and Salmon staging system, 8,2% were in Stage 112.6% in Stage II, 60.5% in Stage III and in 18.8% the information about staging was not available. Fifty percent had an hemoglobin level below 10 g/dL, 30% had a serum creatinine over 2 mg/dL and 28% had a serum calcium level over 10.5 mg/dL. Median survival was 33 months. Twenty percent of patients died within the first six months after diagnosis (early mortality). Predictive factors for early mortality were male sex, thrombocytopenia, anemia, renal failure, hypercalcemia, a beta2-microglobulin >5.5 mg/L and a serum albumin level <3.5 g/dL. There was a correlation between the number of bad prognosis factors present and the probability of early mortality. Conclusions: This group of Chilean patients with MM presented a short survival time, and 20% died within the first six months after diagnosis. More than a half of cases were diagnosed at an advanced stage (Durie and Salmon Stage III). Several factors were associated to early mortality, two of which (beta 2-microglobulin and serum albumin), are included in the new International Staging System for MM
author	Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán
author_facet	Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán
author_sort	Conté L,Guillermo
title	Mieloma múltiple en Chile: Características clínicas y sobrevida
title_short	Mieloma múltiple en Chile: Características clínicas y sobrevida
title_full	Mieloma múltiple en Chile: Características clínicas y sobrevida
title_fullStr	Mieloma múltiple en Chile: Características clínicas y sobrevida
title_full_unstemmed	Mieloma múltiple en Chile: Características clínicas y sobrevida
title_sort	mieloma múltiple en chile: características clínicas y sobrevida
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000900003
work_keys_str_mv	AT contelguillermo mielomamultipleenchilecaracteristicasclinicasysobrevida AT figueroamgaston mielomamultipleenchilecaracteristicasclinicasysobrevida AT loisvvivianne mielomamultipleenchilecaracteristicasclinicasysobrevida AT cabreracmariaelena mielomamultipleenchilecaracteristicasclinicasysobrevida AT leonralvaro mielomamultipleenchilecaracteristicasclinicasysobrevida AT garcialhernan mielomamultipleenchilecaracteristicasclinicasysobrevida AT rojasrhernan mielomamultipleenchilecaracteristicasclinicasysobrevida
_version_	1718436336924360704

Mieloma múltiple en Chile: Características clínicas y sobrevida

Ejemplares similares